Navigation Links
OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
Date:12/10/2007

ATLANTA Oregon Health & Science University Cancer Institute researcher Jeff Tyner, Ph.D., has created a way to identify proteins that are candidates for targeted therapy in acute myeloid leukemia using an assay that yields results in just four days. This research will be presented at the American Society of Hematology annual meeting in Atlanta, on Monday, Dec. 10, at 8:15 a.m.

This functional assay, called RAPID, because it rapidly delivers the information, has the capability of telling researchers which actual proteins from the tyrosine kinase family are contributing to an individual patients cancer.

If you know what protein is driving the cancer, you have the ability to target that protein and stop it. With this knowledge it may be possible to match targeted drugs with the appropriate patient. It may also be possible to identify mechanisms as to why certain leukemias respond well to therapy and why others may not. The real novelty of our work is that we have performed this assay directly on patient samples. It gets us one step closer to the clinic and personalized medicine, said Tyner, a fellow in hematology/ medical oncology, OHSU School of Medicine.

This research has several important aspects. First, it will enable researches to more quickly compile a database of mutant genes that cause cancer. That will enable better diagnosis in the future using DNA sequencing technology. Second, it is possible that this technology may, in the future, be adapted for direct clinical use for diagnostic purposes. In this manner, the RAPID screen could be run on a patients malignant cells, and the appropriate drug could then be determined to treat that patient. Thirdly, the assay can be completed in just four days, whereas previous technologies could take months to years to yield similar information.

Tyner came about his discovery as many scientists do: trial and error and then success.

We were initially screening for these targets by doing large-scale DNA sequencing, looking for mutations. This strategy was not as successful as we had hoped, so we decided that an assay that could functionally screen cells and give us some idea based on what killed cells and what didnt kill cells would be a better place to start. We could then work backward to find the actual mutation underlying that phenotype. RNAi (the name of the technology we use) seemed an ideal platform for this because it allows you to knock down the expression of individual genes, Tyner said.


'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief ... advancements to physician colleagues, skilled nursing facility medical directors and other clinicians at ... of Wound Care." , "At many of these conferences we get to educate ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...  EpiVax, Inc., a leader in the fields ... announced the launch of EpiVax Oncology Inc., a ... cancer vaccines. EpiVax has provided $500,000 in seed ... technologies to the new precision immunotherapy venture. Gad ... as Chief Executive Officer. Gad brings over 25 ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
Breaking Medicine Technology: